AMRN AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock has a lower value rating; if aiming for value investing, existing long-term positions might require gradual reduction.
AMRN Current Performance
0.64%
Amarin corporation plc
1.19%
Avg of Sector
1.11%
S&P500
Top 10 High Relevance to AMRN
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
SGMT | Sagimet biosciences inc | - | 1 | 3 | 2 | 1 | |
SAGE | Sage therapeutics inc | 3 | 1 | 2 | 2 | 1 | |
KYMR | Kymera therapeutics inc | 3 | 4 | 4 | 3 | 1 | |
HRTX | Heron therapeutics inc | 4 | 3 | 3 | 3 | 1 | |
RCEL | Avita medical inc | 1 | 3 | 2 | 2 | 1 |
- SGMT Sagimet biosciences incValue -Trend 1Swing Trading 3Whale Interest 2Dividend 1See more
AMRN Profile
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.